Papers on
DDR2
Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.Mountzios et al., Manchester, United Kingdom. In Cancer Treat Rev, May 2015
Nevertheless, in the recent years a number of other oncogenic drivers beyond EGFR and ALK inhibition have emerged as novel molecular targets with potential therapeutic implications, including mutations in the genes KRAS, BRAF, HER2, PI3KCA and DDR2, as well as ROS1 and RET rearrangements and MET, HER2 and FGFR1 gene amplifications.
Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.Diebold et al., Luzern, Switzerland. In Oncol Res Treat, 2014
Next generation sequencing revealed no further EGFR-mutated cases, but reported in 15 (94%) of the tumors mutations in other genes (ALK, BRAF, DDR2, KEAP1, MET, PTEN, STK11) previously associated with NSCLC.
Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.Liang et al., Beijing, China. In Plos One, 2014
Mutation profiling of the EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 genes were carried out using next-generation sequencing (NGS), Sanger sequencing, and quantitative polymerase chain reaction (QPCR) in 9 successfully amplified cases.
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.Rothschild, Basel, Switzerland. In Cancers (basel), 2014
The scope of this review is to discuss recent data on novel molecular targets as ROS1, BRAF, KRAS, HER2, c-MET, RET, PIK3CA, FGFR1 and DDR2.
Molecular testing in lung cancer in the era of precision medicine.Olszewski et al., Graz, Austria. In Transl Lung Cancer Res, 2014
After EGFR several other driver genes such as echinoderm microtubule associated protein like 4-AL-Kinase 1 (EML4-ALK1), c-ros oncogene 1, receptor tyrosine kinase (ROS1), discoidin domain receptor tyrosine kinase 2 (DDR2), fibroblast growth factor receptor 1 (FGFR1) were discovered, and more to come.
New targetable oncogenes in non-small-cell lung cancer.Jänne et al., Boston, United States. In J Clin Oncol, 2013
A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements.
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.Paik et al., New York City, United States. In Lancet Oncol, 2012
Additionally, evidence of unique biology has emerged with the discovery of SOX2 amplification, NFE2L2 and KEAP1 mutations, PI3K pathway changes, FGFR1 amplification, and DDR2 mutations.